Moffitt Cancer Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Moffitt Cancer Center brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 3623. Its program centres on myelodysplastic syndromes and on bringing bispecific antibodies and CAR T into everyday lymphoma and leukemia care. It also reports real-world evidence on myeloma treatment patterns and outcomes in US practice.
| Organization | ASH 2026 Attendance |
|---|---|
Moffitt Cancer Center Tampa, FL | |
NCI-designated comprehensive cancer center in Tampa, Florida, working on cancer prevention, treatment, research and training. | Booth Exhibiting at Booth 3623 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 11:00am–2:00pm Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session Are We There Yet? Improving Outcomes in MDS Assessing and treating myelodysplastic syndromes, marrow failure cancers of older adults that can turn into acute myeloid leukemia, using newer risk systems. Session Medical Educators' Symposium Practical strategies for medical educators on time management, wellness, inclusive learning spaces, and teaching with AI, apps, and social media. |
Instantly find 20 buyers from Moffitt Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction